Sphere Fluidics

Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for single-cell analysis and isolation, today shared details of Cyto-Mine® Chroma, the second generation of its flagship Cyto-Mine platform.

This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development.

In this Teach Me in 10 video, we'll explore the acceleration of single-cell analysis and screening within the drug discovery process.

In this article, we highlight various high-throughput screening strategies being used to interrogate large libraries of compounds and hear from researchers working to further streamline specific approaches to increase speed and improve quality and accuracy.

Cyto-Mine® can simplify and accelerate your day-to-day operations in cell line development, antibody discovery, and beyond. It’s powered by our picodroplet technology to screen and analyze millions of individual cells and isolate those rare ‘hits’ with monoclonality assured. And all in a single, integrated platform with minimal ‘hands-on’ time.

This app note highlights a uniquely protective environment to support cell viability and integrity during incubation and shield cells against shear stress during subsequent analysis.

Generating a highly expressing, regulatory compliant clonal cell line is key when developing a biopharmaceutical. Yet cell line development is labor-intensive, time consuming and costly.

The production of a high-quality and productive cell line requires both an expression system which yields high expressing clones and a workflow which allows selection of the highest producing clones.

In this webinar, you’ll discover how combining a single-cell analysis platform with a novel glutamine synthetase-Chinese hamster ovary (GS-CHO) expression system can yield highly productive, scalable, clonal cell lines for developing biopharmaceuticals.

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.

Sphere Fluidics has announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice regulations enforced by the US FDA.

Sphere Fluidics announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.